ZEALAND PHARMA/S (NASDAQ:ZEAL)’s stock price reached a new 52-week high on Thursday . The stock traded as high as $23.96 and last traded at $23.68, with a volume of 9744 shares traded. The stock had previously closed at $23.44.
ZEAL has been the topic of several research analyst reports. TheStreet downgraded shares of ZEALAND PHARMA/S from a “c” rating to a “d+” rating in a research report on Friday, August 16th. Morgan Stanley boosted their target price on shares of ZEALAND PHARMA/S from $29.00 to $30.00 and gave the stock an “overweight” rating in a research report on Monday, August 19th. Zacks Investment Research downgraded shares of ZEALAND PHARMA/S from a “hold” rating to a “sell” rating in a research report on Sunday. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $32.00 price objective (up from $29.00) on shares of ZEALAND PHARMA/S in a report on Thursday, August 15th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and three have assigned a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus target price of $27.33.
The firm’s fifty day moving average price is $21.64 and its 200 day moving average price is $20.00. The firm has a market capitalization of $661.92 million, a PE ratio of 7.89 and a beta of 1.98.
A hedge fund recently raised its stake in ZEALAND PHARMA/S stock. Farallon Capital Management LLC grew its holdings in ZEALAND PHARMA/S (NASDAQ:ZEAL) by 5.4% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,000,000 shares of the company’s stock after acquiring an additional 51,300 shares during the period. Farallon Capital Management LLC owned about 3.25% of ZEALAND PHARMA/S worth $21,550,000 at the end of the most recent quarter. Institutional investors and hedge funds own 9.38% of the company’s stock.
About ZEALAND PHARMA/S (NASDAQ:ZEAL)
Zealand Pharma A/S, a biotechnology company, engages in the discovery, design, and development of peptide therapeutics-based medicines in Denmark. It has a portfolio of proprietary medicines in late-stage clinical development focusing on gastrointestinal and metabolic diseases. The company markets lixisenatide for the treatment of type 2 diabetes under the brand names of Adlyxin and Lyxumia; and a combination of lixisenatide and insulin glargine for the treatment of type 2 diabetes under the brand names of Soliqua 100/33 and Suliqua.
Featured Article: Understanding the different types of bonds
Receive News & Ratings for ZEALAND PHARMA/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZEALAND PHARMA/S and related companies with MarketBeat.com's FREE daily email newsletter.